Jenkins: FDA Should Remove Avastin’s MBC Indication Despite Pending Trials

Allowing Genentech to finish conducting an additional Avastin trial before removing the drug’s metastatic breast cancer (MBC) indication “could undermine the integrity of the accelerated approval program,” FDA Office of New Drugs Director John Jenkins said Tuesday.
Drug Industry Daily